Abbott Laboratories Launches Oncodetect Molecular Residual Disease Test

09:49 AM EDT, 10/26/2026 (MT Newswires) -- Abbott Laboratories (ABT) has commercially launched the Oncodetect molecular residual disease, or MRD, test, the company said Monday. The personalized test is designed to deliver molecular insights during and after cancer treatment, using the patient's tumor sample to identify unique DNA markers, Abbott said. Oncodetect is backed by whole-genome sequencing and the MAESTRO technology to expand variant discovery, the company added. The test is available for patients with solid tumors but has not been cleared or approved by the US Food and Drug Administration. Price: 104.03, Change: +0.33, Percent Change: +0.32